Covagen Initiates Phase Ib/IIa Study of Bispecific anti-TNF/IL-17A FynomAb COVA322 - NBC Right Now/KNDO/KNDU Tri-Cities, Yakima, WA |

Covagen Initiates Phase Ib/IIa Study of Bispecific anti-TNF/IL-17A FynomAb COVA322

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Covagen

COVA322 is First of Covagen's Bispecific FynomAbs to Enter Clinical Trials

ZURICH-SCHLIEREN, Switzerland, May 5, 2014 /PRNewswire/ -- Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb® developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39 patients with psoriasis and evaluate safety as well as biological activity of COVA322. Enrollment in the trial and dosing of COVA322 has begun for the first cohort of patients.

"With COVA322, Covagen has moved its first proprietary FynomAb into the clinic," said Mathias Locher, Ph.D., chief development officer of Covagen. "COVA322 has a novel mechanism of action by simultaneously inhibiting both TNF and IL-17A. This dual inhibition has the potential to result in superior efficacy compared to current treatment options for rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases."

Julian Bertschinger, Ph.D., chief executive officer of Covagen added: "We believe this first clinical study with COVA322 in psoriasis patients may indicate its significant potential to improve the treatment of inflammatory diseases and help to validate the capabilities of our proprietary bispecific FynomAb platform. We expect to have top-line data in the first quarter of 2015."

The primary aim of the Phase Ib/IIa trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending dose of COVA322. The randomized, double-blind, placebo-controlled, multi-center study will be conducted in Germany in 39 patients with psoriasis. Secondary endpoints include readouts on psoriatic skin lesions as well as biological responses measured in skin biopsies.

About Covagen
Covagen is a clinical stage company that develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. Fynomers are small binding proteins that can be engineered to bind an antigen of interest. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Covagen is a privately held Swiss Biotech company with an internal lead bispecific anti-TNF/IL-17A FynomAb COVA322. In 2012, Covagen entered into a strategic alliance, which was recently expanded, with Mitsubishi Tanabe Pharma Corporation for the development of bispecific FynomAbs. In December 2013 and February 2014, Covagen closed a Series B financing round with a total of CHF 45 million that primarily supports Phase I and Phase II developments of COVA322.

For more information please visit www.covagen.com

 

Corporate Contact:

Media Contacts:

Elias Papatheodorou 

Matt Middleman, M.D.

Chief Business Officer 

Tony Russo, Ph.D.

Tel: +41 (0) 44 732 46 60 

Russo Partners

info@covagen.com 

Tel: +1212 845 4272


Tel: +1212 845 4251


matt.middleman@russopartnersllc.com


tony.russo@russopartnersllc.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KHQ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.